What is Lartruvo (olaratumab) for?
Lartruvo (olaratumab) is a cancer medicine (targeted therapy) used in combination with doxorubicin to treat adults with advanced soft tissue sarcoma, a type of cancer that affects the soft, supportive tissues of the body such as muscles, blood vessels, and fat tissue2. It is used for patients who cannot undergo surgery or radiotherapy (treatment with radiation) and who have not been previously treated with doxorubicin1,2. Doxorubicin is a cancer medication widely approved for the treatment of different forms of cancer5,6,7.
How does Lartruvo (olaratumab) work?
Lartruvo is a targeted therapy. The active substance in Lartruvo, olaratumab, is a monoclonal antibody that has been designed to recognise and attach to a protein called ‘platelet-derived growth factor receptor alpha’ (PDGFRα). This protein is often found on the surface of cells where it plays a role in regulating cell multiplication. In cancers such as soft tissue sarcoma, this protein is present in high levels or is overactive, causing cells to become cancerous. By attaching to PDGFRα on sarcoma cells, Lartruvo is expected to block the activity of this protein, thereby slowing down the growth of the cancer2.
Where has Lartruvo (olaratumab) been approved?
Lartruvo (olaratumab) was approved for soft tissue sarcoma (STS) that cannot be treated with surgery or radiotherapy and that has been previously treated with doxorubicin2,3,4 by:
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
How is Lartruvo (olaratumab) taken?
The standard dosage is1,3:
Administer in combination with doxorubicin for up to 8 cycles of treatment, followed by Lartruvo monotherapy in patients whose disease has not progressed. Doxorubicin is given on day 1 of each cycle following the Lartruvo (olaratumab) infusion.
Complete information about Lartruvo (olaratumab) dosage and administration can be found in the official prescribing information listed in our resources section1,3.
Note: Please consult with your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Lartruvo (olaratumab)?
Common adverse reactions
The most common adverse reactions of Lartruvo (olaratumab) plus doxorubicin listed in the prescribing information include1,3:
abnormal blood counts (lymphopenia, neutropenia, thrombocytopenia, hyperglycemia, elevated aPTT, hypokalemia, and hypophosphatemia).
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include1,3:
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,3.